Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BioNTech : Shares Rise After Data Shows Efficacy of COVID-19 Vaccine's Booster Dose

10/21/2021 | 12:48pm EST


© MT Newswires 2021
All news about BIONTECH SE
05:10pBIONTECH : will take two weeks to assess vaccine against latest Covid variant - Form 6-K
PU
04:50pBIONTECH : Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 5 ..
PU
02:41pNovavax testing vaccine that targets new COVID-19 variant
RE
01:52pADRs Close Lower; BioNTech Rises, Carnival Drops
DJ
12:07pCovid-19 Vaccine Maker Stocks Higher Amid Variant Concerns
DJ
12:06pNew purchase in the MarketScreener USA Portfolio
12:03pFDA Places Clinical Hold on Phase 3 Study for Ocugen COVID-19 Vaccine Covaxin
MT
11:52aBioNTech Up Nearly 21%, On Pace for Largest Percent Increase Since May 2020 -- Data Tal..
DJ
11:12aEuropean ADRs Down Nearly 3% Friday as Travel, Energy, Financial Shares Slump
MT
09:19aHealth Care Stocks Mixed Pre-Bell Friday
MT
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 17 474 M 19 783 M 19 783 M
Net income 2021 9 220 M 10 438 M 10 438 M
Net cash 2021 9 793 M 11 087 M 11 087 M
P/E ratio 2021 9,48x
Yield 2021 -
Capitalization 84 049 M 84 049 M 95 153 M
EV / Sales 2021 4,25x
EV / Sales 2022 3,76x
Nbr of Employees 2 800
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 348,00 €
Average target price 259,68 €
Spread / Average Target -25,4%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE273.85%73 606
GILEAD SCIENCES, INC.20.27%87 895
REGENERON PHARMACEUTICALS34.17%67 771
WUXI APPTEC CO., LTD.24.40%62 328
VERTEX PHARMACEUTICALS-21.20%47 352
BEIGENE, LTD.36.04%32 981